Dendrite to Present at Bear Stearns 19th Annual Healthcare Conference; September 11, 2006 at the Grand Hyatt in New York City

Executives from Dendrite International, Inc. (NASDAQ:
DRTE) will be speaking at the Bear Stearns 19th Annual Healthcare
Conference, which will be held September 11-12, 2006, at the Grand
Hyatt in New York City. The conference will feature presentations by
companies covering all sectors of the healthcare industry.
   On Monday, September 11, 2006 at 11:30 am ET (Eastern Time), John
Bailye, Chairman and CEO and Jeffrey Bairstow, EVP and CFO will
discuss Dendrite's business and future growth opportunities. A link to
a live and replayed webcast will be available at www.dendrite.com in
the Investors Highlights section.

   About Dendrite

   Founded in 1986, Dendrite International (NASDAQ: DRTE) enables
sales, marketing, clinical and compliance solutions for the global
pharmaceutical industry. The Company's clients are located in more
than 50 countries and include the world's top 20 pharmaceutical
companies. For more information, please visit www.dendrite.com. For
more information on OPUS Health, please visit www.opushealth.com.

   Note: Dendrite is a registered trademark of Dendrite
International, Inc.

   This document may contain forward-looking statements that may be
identified by such forward-looking terminology as "expect," "believe,"
"anticipate," "will," "intend," "plan," "target," "outlook,"
"guidance," and similar statements or variations. Such forward-looking
statements are based on our current expectations, estimates,
assumptions and projections and involve significant risks and
uncertainties, including risks which may result from our dependence on
the pharmaceutical industry; our fixed expenses in relation to
fluctuating revenues and variations in customers' budget cycles;
dependence on certain major customers, including the risk associated
with one substantial customer currently assessing its U.S. sales force
effectiveness services needs; our ability to successfully implement
our Operational Effectiveness program and to achieve the cost savings
in the amounts and time periods expected or budgeted; changes in
demand for our products and services attributable to any weakness
experienced in the economy or mergers, acquisitions and consolidations
in the pharmaceutical industry; risks associated with foreign currency
fluctuations and our ability to adapt and respond successfully to
other unique risks involved in our non-U.S. operations; integrating
the entities we acquire; and our ability to effectively manage our
growth. Other important factors that should be reviewed and carefully
considered are included in the company's 10-K, 10-Qs, and other
reports filed with the SEC. Actual results may differ materially. The
company assumes no obligation for updating any such forward-looking
statements to reflect actual results, changes in assumptions or other
changes affecting such forward-looking statements and the information
provided in this press release should not be construed as updating,
modifying or confirming the company's most recent financial outlook or
guidance.